Head and Neck Cancer
Researchers identified 23,450 trial sites; a majority of them began before 2020.
The researchers hypothesized that the prognostic value of diurnal cortisol aberrations will hold in HNC.
Researchers aimed to find a marker to accurately predict the prognosis of HNSCC and to find novel immune targets.
The combo's use for conjunctival melanoma demonstrates the combinations high efficacy in treating complex disease.
The single-center, prospective study evaluated patient questionnaires to assess quality of life and physical function.
BANF1 is a prognostic biomarker that can promote tumor expression in patients with HNSCC.
Oral bacteria are a risk factor for head and neck squamous cell cancer.
A novel predictive digital pathology biomarker demonstrates high predictive response in HNC.
Advertisement
Expert Interviews on Oncology
Advertisement
DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.